IL1B and pancreatic neoplasm: Interestingly, this axis may be a valuable therapeutic target to potentially circumvent chemoresistance in pancreatic cancer as targeting IRAK4 or IL-1β could render PDAC tumors less fibrotic and more sensitive to gemcitabine and, potentially, other chemotherapeutic agents (Zhang D. et al., 2018; Elahi-Gedwillo et al., 2019).